You are here: Industry Insights > AstraZeneca

News List

AstraZeneca signs major cancer drug deal bbc
April 18, 2019
British pharmaceutical giant AstraZeneca has signed a deal with Japanese firm Daiichi Sankyo to help develop and sell the cancer drug trastuzumab deruxtecan.
AZ finds lack of lung cancer info available for patients pharmatimes
April 16, 2019
New AstraZeneca research has shown significant gaps in online sources of information for lung cancer patients.
AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal pharmaceutical-technology
April 11, 2019
AstraZeneca has entered a deal worth up to $6.9bn with Daiichi Sankyo to develop and commercialise cancer drug trastuzumab deruxtecan...
Lynparza gains EU approval for type of metastatic breast cancer pharmatimes
April 11, 2019
AstraZeneca and MSD‘s Lynparza (olaparib) has been approved by the European Commission for the treatment of germline BRCA-mutated HER2-negative metastatic breast cancer.
AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza gains EU approval in breast cancer firstwordpharma
April 10, 2019
AstraZeneca and Merck & Co. announced Wednesday that the European Commission approved Lynparza (olaparib) ……
AstraZeneca's Fasenra keeps the heat on GSK's Nucala with new phase 2 data fiercepharma
April 10, 2019
AstraZeneca’s Fasenra is already pressuring GlaxoSmithKline's Nucala in severe eosinophilic asthma, and new data could help set up a showdown between the two in another indication.
Continuous wet granulation manufacturing collaboration europeanpharmaceuticalreview
April 10, 2019
The new facility, built as part of a project called PROSPECT CP, will include blending and feeding of raw materials, twin screw wet granulation, drying and ultimately tabletting…
Continuous wet granulation manufacturing collaboration europeanpharmaceuticalreview
April 10, 2019
The new facility, built as part of a project called PROSPECT CP, will include blending and feeding of raw materials, twin screw wet granulation, drying and ultimately tabletting…
NICE recommends AstraZeneca’s Imfinzi through Cancer Drugs Fund By Allie Nawrat pharmaceutical-technology
April 03, 2019
The UK’s National Institute of Health and Care Excellence (NICE) has published its final guidance for AstraZeneca’s Imfinzi (durvalumab), in which it recommends the immunotherapy for use by the NHS through the Cancer Drugs Fund.
AstraZeneca to support creation of Life Sciences Innovation Park in China biospectrumasia
April 02, 2019
AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi^

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page